Search

American Manufacturing Surges to Four-Year High as Factory Activity Expands

The White House announced on April 22, 2026, that the Institute for Supply Management's key manufacturing index registered its third consecutive month of expansion at its highest reading since 2022. Major companies announced significant U.S. manufacturing investments including U.S. Steel restarting its Gary Tin Mill in Indiana (225 jobs), Apple committing $600 billion over four years, Nvidia pledging $500 billion for AI chip production, and Johnson & Johnson investing $55 billion in new U.S. manufacturing. Foreign pharmaceutical companies AstraZeneca ($50 billion), Bristol Myers Squibb ($40 billion), and GSK ($30 billion) also announced major U.S. manufacturing expansions.

AREXVY RSV Vaccine Approved for Rare Pediatric Disease Priority Review Voucher

The FDA granted a Rare Pediatric Disease Priority Review Voucher to AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) under Docket No. FDA-2026-N-3446. The voucher, published at 91 FR 20460, was awarded upon approval of the vaccine product.AREAS XVY is manufactured by GSK and is indicated for active immunization against RSV disease in adults 60 years and older, and in infants through maternal immunization.

GSK Withdraws Wellcovorin (Leucovorin Calcium) NDA Approval

FDA withdrew approval of NDA 018342 for Wellcovorin (leucovorin calcium) tablets at GlaxoSmithKline's written request. GSK notified FDA that the drug products are no longer marketed. Existing inventory may continue to be dispensed until depleted or reaching expiration dates.

GSK Withdraws Wellcovorin NDA - Leucovorin Calcium Tablets Discontinued

FDA withdrew approval of NDA 018342 for Wellcovorin (leucovorin calcium) tablets at GSK's written request after the company notified the Agency the drug products were no longer marketed. GSK waived its opportunity for a hearing and requested withdrawal under 21 CFR 314.150(c). Existing inventory may be dispensed until depleted or until expiration dates.

Compositions and Methods for Enhancing Wnt Signaling for Treating Cancer

USPTO published patent application US20260091038A1 on April 2, 2026, disclosing compositions and methods for enhancing Wnt signaling pathway activities for treating cancer, particularly cancers with APC gene mutations. The application covers pharmaceutical compositions containing GSK-3 inhibitors, preferably LY2090314, encapsulated in nanoparticles. Inventors are George Eng, Omer Yilmaz, and Jonathan Braverman. Application number 19294146 was filed August 7, 2025.

BaFin Orders Unauthorized Insurance Business Cessation

BaFin has ordered Deutsche Krankenvorsorge GmbH and Deutsche Krankenunterstützungskasse e.V. to immediately cease their unauthorized insurance business. The companies offered a 'Private Patient' coverage that effectively bypassed statutory health insurance, leading to BaFin's intervention.

USPTO Trademark Registration: RAZORBACK (Welder's Gloves)

The USPTO has registered the trademark 'RAZORBACK' (TM73549178) for welder's work gloves made of pigskin. The registration was finalized on March 25, 2026, with an initial filing date of July 22, 1985.